Segmentation of dynamic contrast enhanced magnetic resonance imaging data

References

• Padhani AR, Dzik-Jurasz A. Perfusion MR imaging of extracranial tumor angiogenesis. Top Magn Reson Imaging 2004; 15: 41–57
   PubMedGoogle Scholar
• Horsman MR, Siemann DW. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 2006; 66: 11520–39
   PubMed Web of Science ®Google Scholar
• Murata R, Siemann DW, Overgaard J, Horsman MR. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother Oncol 2001; 60: 155–61
   PubMed Web of Science ®Google Scholar
• Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002; 62: 3408–16
   PubMed Web of Science ®Google Scholar
• Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ, et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003; 21: 2831–42
   PubMed Web of Science ®Google Scholar
• Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: Magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003; 21: 4428–38
   PubMed Web of Science ®Google Scholar
• Beauregard DA, Hill SA, Chaplin DJ, Brindle KM. The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability. Cancer Res 2001; 61: 6811–5
   PubMed Web of Science ®Google Scholar
• Beauregard DA, Pedley RB, Hill SA, Brindle KM. Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS. NMR Biomed 2002; 15: 99–105
   PubMed Web of Science ®Google Scholar
• Maxwell RJ, Wilson J, Prise VE, Vojnovic B, Rustin GJ, Lodge MA, et al. Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI. NMR Biomed 2002; 15: 89–98
   PubMed Web of Science ®Google Scholar
• Bentzen L, Vestergaard-Poulsen P, Nielsen T, Overgaard J, Bjørnerud A, Briley-Saebø K, et al. Intravascular contrast agent-enhanced MRI measuring contrast clearance and tumor blood volume and the effects of vascular modifiers in an experimental tumor. Int J Radiat Oncol Biol Phys 2005; 61: 1208–15
   PubMed Web of Science ®Google Scholar
• Salmon BA, Salmon HW, Siemann DW. Monitoring the treatment efficacy of the vascular disrupting agent CA4P. Eur J Cancer 2007; 43: 1622–9
   PubMedGoogle Scholar
• Salmon BA, Siemann DW. Characterizing the tumor response to treatment with combretastatin A4 phosphate. Int J Radiat Oncol Biol Phys 2007; 68: 211–7
   PubMed Web of Science ®Google Scholar
• Nielsen T, Murata R, Maxwell RJ, Stødkilde-Jørgensen H, Ostergaard L, Horsman MR. Preclinical studies to predict efficacy of vascular changes induced by combretastatin a-4 disodium phosphate in patients. Int J Radiat Oncol Biol Phys 2008; 70: 859–66
   PubMed Web of Science ®Google Scholar
• Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003; 300(5622)1155–9
   PubMed Web of Science ®Google Scholar
• Horsman MR, Nielsen T, Østergaard L, Overgaard J. Radiation administered as a large single dose or in a fractionated schedule: Role of the tumour vasculature as a target for influencing response. Acta Oncol 2006; 45: 876–80
   PubMed Web of Science ®Google Scholar
• Zahra MA, Hollingsworth KG, Sala E, Lomas DJ, Tan LT. Dynamic contrast-enhanced MRI as a predictor of tumour response to radiotherapy. Lancet Oncol 2007; 8: 63–74
   PubMed Web of Science ®Google Scholar
• Overgaard J. Simultaneous and sequential hyperthermia and radiation treatment of an experimental tumor and its surrounding normal tissue in vivo. Int J Radiat Oncol Biol Phys 1980; 6: 1507–17
   PubMed Web of Science ®Google Scholar
• Kallman RF, Silini G, Putten LMV. Factors influencing the quantitative estimation of the in vivo survival of cells from solid tumors. J Natl Cancer Inst 1967; 39: 539–49
   PubMed Web of Science ®Google Scholar
• Pedersen M, Mørkenborg J, Jensen FT, Stødkilde-Jørgensen H, Djurhuus JC, Frokiaer J. In vivo measurements of relaxivities in the rat kidney cortex. J Magn Reson Imaging 2000; 12: 289–96
   PubMedGoogle Scholar
• Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: Standardized quantities and symbols. J Magn Reson Imaging 1999; 10: 223–32
   PubMed Web of Science ®Google Scholar
• Furman-Haran E, Grobgeld D, Degani H. Dynamic contrast-enhanced imaging and analysis at high spatial resolution of MCF7 human breast tumors. J Magn Reson 1997; 128: 161–71
   PubMed Web of Science ®Google Scholar
• Horsman MR, Finch A, Overgaard J. Erythropoietin improves the oxygen carrying capacity of mouse blood without changing hypoxia in a murine tumour model. Eur J Cancer Suppl 2003; 1: S13
   Google Scholar
• Thoeny HC, Keyzer FD, Vandecaveye V, Chen F, Sun X, Bosmans H, et al. Effect of vascular targeting agent in rat tumor model: Dynamic contrast-enhanced versus diffusion-weighted MR imaging. Radiology 2005; 237: 492–9
   PubMed Web of Science ®Google Scholar